| Chapter 12: His Appointed Rounds |
|
|
| Written by Dr. Mel | |||||
| Wednesday, 27 June 2007 | |||||
Page 3 of 3 At that point, he began taking a number of different treatments. Fortunately, by that time, a number of options became available for myeloma patients. Fran had most of them – thalidomide, velcade, revlimid, and combinations with steroids. But the myeloma was becoming very aggressive, and in early 2007, he underwent a second transplant. During his first one in 1997, additional stem cells were harvested and frozen, just in case a second transplant would be needed. The doctors used those stem cells for his second transplant, but the procedure was not very effective this time – 2007 was not a good year for Fran. He really never recovered from that second transplant, and he died during the spring. But his spirit and courage never waned. I can remember talking with him two days before he passed away. I asked him how he was doing. He said, “Fine, I’m doing fine.” Fran always said he was fine. I never had a conversation with him when he failed to say how fine he was feeling, and from his perspective and in his world, he was always fine – even when he was clinging to life in the Intensive Care Unit. It is little wonder that his two grandsons, Philip and Spencer, just ten and seven years old, spent time with him during these precious hours and told him about all the that he had done for them and how much they appreciated him. They loved their trip to Disney World, and they always had fun washing his antique cars.
Fran taught us all how to live, even during those days when life was slipping away from himself. And for Kathy, Fran was truly the love of her life, but she does say that she’ll never try roller skating again. |
|||||
| < Prev | Next > |
|---|
Multiple Myeloma News Update
-
Immunomedics to Present At 50th ASH Annual Meeting
GlobeNewsWire (press release), CA - 5 hours ago
... Moscone Center, Hall A) --"First Trial of Humanized Anti-CD74 Monoclonal Antibody (MAb), Milatuzumab, in Multiple Myeloma" (Publication No. ... -
Xencor to Present New Data from Pre-Clinical Antibody Programs at ...
MarketWatch - 6 hours ago
... XmAb5485, Exhibits Potent Activity In Vitro and In Vivo Against Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma," on Tuesday, ... -
The International Myeloma Foundation Says Patient Experience ...
MarketWatch - 6 hours ago
Multiple myeloma is a cancer of cells in the bone marrow that affects blood cell production. It cannot be cured, however new therapies used in combination ... -
InforSense Partners With the UK's South London and Maudsley NHS ...
MarketWatch - 10 hours ago
... research into diseases such as Alzheimer's, breast cancer and multiple myeloma," said Jonathan Sheldon, Chief Scientific Officer at InforSense. ...
InforSense Partners With the UK's South London and Maudsley NHS ... International Business Times
all 13 news articles -
Astex presents updates on AT7519 and AT9283 at the American ...
PharmaLive.com (press release), PA - 20 hours ago
Together, these data provide the rationale for further clinical evaluation of AT7519 in the treatment of multiple myeloma and CLL and suggests that AT7519 ... -
Dec 6, 2008 Monthly meeting of the NE TN Multiple Myeloma Support ...
Kingsport Times News, TN - Nov 30, 2008
By Ellen Barrett The Northeast Tennessee Multiple Myeloma Support Group will have it’s next monthly meeting at the Health Resources Center Annex at the Mall ... -
Multiple Myeloma Research Foundation’s (MMRF) annual gala raises ...
Norwalk Plus Magazine - Nov 25, 2008
By Press Release The Multiple Myeloma Research Foundation (MMRF) raised over $1.5 million at its 12th annual "Friends for Life" Fall Gala held on November 1 ... -

HemOncTodayLast decade brought progress in treatment of multiple myeloma
HemOncToday, NJ - Nov 25, 2008
Major strides have been made in the treatment of multiple myeloma in the last decade, with the advent of new agents such as thalidomide, lenalidomide and ...












